Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05795842 · ClinicalTrials.gov registry record

DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)

A clinical trial of Stroke, Ischemic, sponsored by Emory University.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT05795842: Recruiting study of Stroke, Ischemic, sponsored by Emory University.

NCT05795842 is a study of Stroke, Ischemic that is actively recruiting participants, run by Emory University. The registered enrollment target is 500 participants, above the 274-participant average among 33 other Stroke, Ischemic trials with a reported enrollment target (82% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05795842, a study of Stroke, Ischemic, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

Atrial Fibrillation (AF) is an abnormal heart rhythm. Because AF is often asymptomatic, it often remains undiagnosed in the early stages. Anticoagulant therapy greatly reduces the risks of stroke in patients diagnosed with AF. However, diagnosis of AF requires long-term ambulatory monitoring procedures that are burdensome and/or expensive. Smart devices (such as Apple or Fitbit) use light sensors (called "photoplethysmography" or PPG) and motion sensors (called "accelerometers") to continuously record biometric data, including heart rhythm. Smart devices are already widely adopted. This study seeks to validate an investigational machine-learning software (also called "algorithms") for the long-term monitoring and detection of abnormal cardiac rhythms using biometric data collected from consumer smart devices. The research team aims to enroll 500 subjects who are being followed after a stroke event of uncertain cause at the Emory Stroke Center. Subjects will undergo standard long-term cardiac monitoring (ECG), using FDA-approved wearable devices fitted with skin electrodes or implantable continuous recorders, and backed by FDA-approved software for abnormal rhythm detection. Patients will wear a study-provided consumer wrist device at home, for the 30 days of ECG monitoring, 23 hours a day. At the end of the 30 days, the device data will be uploaded to a secure cloud server and will be analyzed offline using proprietary software (called "algorithms") and artificial intelligence strategies. Detection of AF events using the investigational algorithms will be compared to the results from the standard monitoring to assess their reliability. Attention will be paid to recorded motion artifacts that can affect the quality and reliability of recorded signals. The ultimate aim is to establish that smart devices can potentially be used for monitoring purposes when used with specialized algorithms. Smart devices could offer an affordable alternative to standard-of-care car

Primary Outcome

Sensitivity and specificity of the algorithm will be calculated at study completion

Conditions Studied

Interventions

  • DEVICE wearable wristband model
  • OTHER Samsung Galaxy Watch 6
  • DEVICE Standard of care extended ECG monitoring

Study Locations (1)

Georgia

  • Emory Clinic - Atlanta

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2023-03-21
Est. Completion 2028-12
Emory University

1,208 total trials

What NCT05795842 shows while recruiting

NCT05795842 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 274-participant average among 33 other Stroke, Ischemic trials with a reported enrollment target (82% higher).

The record links to 1 condition, with Stroke, Ischemic appearing as the primary indexed condition, and to 3 interventions - of which wearable wristband model is the first listed.

NCT05795842 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT05795842 about?

NCT05795842 is a clinical study titled "DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)". Atrial Fibrillation (AF) is an abnormal heart rhythm. Because AF is often asymptomatic, it often remains undiagnosed in the early stages. Anticoagulant therapy greatly reduces the risks of stroke in patients diagnosed with AF. However, diagnosis of AF requires long-term ambulatory monitoring procedu...

What is the current status of trial NCT05795842?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-03-21. Estimated completion is 2028-12.

What conditions does trial NCT05795842 study?

This clinical trial studies the following conditions: Stroke, Ischemic.

What interventions are being tested in trial NCT05795842?

The interventions under investigation include: wearable wristband model (DEVICE), Samsung Galaxy Watch 6 (OTHER), Standard of care extended ECG monitoring (DEVICE).

Who is sponsoring clinical trial NCT05795842?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05795842 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke, Ischemic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05795842's enrollment target sits among peer trials

500 5th of 33 higher than 29 of 33 other Stroke, Ischemic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke, Ischemic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05795842, the US trial registry maintained by the National Library of Medicine. NCT05795842 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.